Vascular compliance in blood pressure

Current Opinion in Nephrology and Hypertension

Volumn 20, Issue 5, 2011, Pages 457-464

  Raij, Leopoldo ^a,b   Gonzalez Ochoa, Alba M ^a,b  

^a UNIVERSITY OF MIAMI   (United States)

^b VETERANS AFFAIRS MEDICAL CENTER   (United States)

Author keywords

aortic pressure wave; arterial stiffness; pulse pressure; pulse wave velocity; wave reflection

Indexed keywords

AMLODIPINE; ANGIOTENSIN RECEPTOR ANTAGONIST; ATENOLOL; BETA 1 ADRENERGIC RECEPTOR BLOCKING AGENT; CALCIUM CHANNEL BLOCKING AGENT; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; DIURETIC AGENT; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; METOPROLOL; NEBIVOLOL; PERINDOPRIL;

ARTERIAL STIFFNESS; BLOOD PRESSURE; DIASTOLIC BLOOD PRESSURE; HUMAN; ISCHEMIC HEART DISEASE; MORTALITY; PRIORITY JOURNAL; PULSE WAVE; REVIEW; STROKE; SYSTOLIC BLOOD PRESSURE;

AGE FACTORS; AGING; ANTIHYPERTENSIVE AGENTS; ARTERIES; BLOOD PRESSURE; COMPLIANCE; HUMANS; HYPERTENSION; MANOMETRY; PREDICTIVE VALUE OF TESTS; PULSATILE FLOW;

EID: 80051791246     PISSN: 10624821     EISSN: 14736543     Source Type: Journal    
DOI: 10.1097/MNH.0b013e3283499d7b     Document Type: Review

References (99)

1. Gkaliagkousi E, Douma S. The pathogenesis of arterial stiffness and its prognostic value in essential hypertension and cardiovascular diseases. Hippokratia 2009;13:70-75.
2. Nichols WW. Clinical measurement of arterial stiffness obtained from noninvasive pressure waveforms. Am J Hypertens 2005;18:3S-10S. (Pubitemid 40416846)
3. O'Rourke MF, Kelly RP. Wave reflection in the systemic circulation and its implications in ventricular function. J Hypertens 1993;11:327-337. (Pubitemid 23139773)
4. O'Rourke MF, Nichols WW. Aortic diameter, aortic stiffness, and wave reflection increase with age and isolated systolic hypertension. Hypertension 2005;45:652-658. (Pubitemid 40418361)
5. Kass DA. Age-related changes in ventricular-arterial coupling: pathophysiologic implications. Heart Fail Rev 2002;7:51-62. (Pubitemid 34154899)
6. Santhanam L, Christianson DW, Nyhan D, Berkowitz DE. Arginase and vascular aging. J Appl Physiol 2008;105:1632-1642.
7. Nagai Y, Metter EJ, Fleg JL. Increased carotid artery intimal-medial thickness: risk factor for exercise-induced myocardial ischemia in asymptomatic older individuals. Vasc Med 1999;4:181-186. (Pubitemid 29426369)
8. Virmani R, Avolio AP, Mergner WJ, et al. Effect of aging on aortic morphology in populations with high and low prevalence of hypertension and atherosclerosis. Comparison between occidental and Chinese communities. Am J Pathol 1991;139:1119-1129.
9. Lakatta EG. Cardiovascular regulatory mechanisms in advanced age. Physiol Rev 1993;73:413-467.
10. Cohn JN, Quyyumi AA, Hollenberg NK, Jamerson KA. Surrogate markers for cardiovascular disease: functional markers. Circulation 2004;109:IV31-IV46.
11. Franklin SS, Gustin Wt, Wong ND, et al. Hemodynamic patterns of agerelated changes in blood pressure. The Framingham Heart Study. Circulation 1997;96:308-315. (Pubitemid 27298437)
12. Wilkinson IB, Franklin SS, Hall IR, et al. Pressure amplification explains why pulse pressure is unrelated to risk in young subjects. Hypertension 2001;38:1461-1466. (Pubitemid 34033434)
13. Meaume S, Benetos A, Henry OF, et al. Aortic pulse wave velocity predicts cardiovascular mortality in subjects >70 years of age. Arterioscler Thromb Vasc Biol 2001;21:2046-2050. (Pubitemid 34219760)
14. Safar ME. Arterial aging: hemodynamic changes and therapeutic options. Nat Rev Cardiol 2010;7:442-449.
15. London GM, Blacher J, Pannier B, et al. Arterial wave reflections and survival in end-stage renal failure. Hypertension 2001;38:434-438. (Pubitemid 34225679)
16. Blacher J, Asmar R, Djane S, et al. Aortic pulse wave velocity as a marker of cardiovascular risk in hypertensive patients. Hypertension 1999;33:1111-1117. (Pubitemid 29230958)
17. Darne B, Girerd X, Safar M, et al. Pulsatile versus steady component of blood pressure: a cross-sectional analysis and a prospective analysis on cardiovascular mortality. Hypertension 1989;13:392-400. (Pubitemid 19099610)
18. Madhavan S, Ooi WL, Cohen H, Alderman MH. Relation of pulse pressure and blood pressure reduction to the incidence of myocardial infarction. Hypertension 1994;23:395-401. (Pubitemid 24076725)
19. Chae CU, Pfeffer MA, Glynn RJ, et al. Increased pulse pressure and risk of heart failure in the elderly. JAMA 1999;281:634-639. (Pubitemid 29098064)
20. Mitchell GF, Moye LA, Braunwald E, et al. Sphygmomanometrically determined pulse pressure is a powerful independent predictor of recurrent events after myocardial infarction in patients with impaired left ventricular function. SAVE investigators. Survival and ventricular enlargement. Circulation 1997;96:4254-4260. (Pubitemid 28007452)
21. Vaccarino V, Berger AK, Abramson J, et al. Pulse pressure and risk of cardiovascular events in the systolic hypertension in the elderly program. Am J Cardiol 2001;88:980-986. (Pubitemid 33042608)
22. Kostis JB, Lawrence-Nelson J, Ranjan R, et al. Association of increased pulse pressure with the development of heart failure in SHEP. Systolic Hypertension in the Elderly (SHEP) Cooperative Research Group. Am J Hypertens 2001;14:798-803. (Pubitemid 32682248)
23. Franklin SS, Khan SA, Wong ND, et al. Is pulse pressure useful in predicting risk for coronary heart disease? The Framingham heart study. Circulation 1999;100:354-360. (Pubitemid 29362404)
24. O'Donnell CJ, Ridker PM, Glynn RJ, et al. Hypertension and borderline isolated systolic hypertension increase risks of cardiovascular disease and mortality in male physicians. Circulation 1997;95:1132-1137. (Pubitemid 27097822)
25. Wilkinson IB, MacCallum H, Flint L, et al. The influence of heart rate on augmentation index and central arterial pressure in humans. J Physiol 2000;525:263-270. (Pubitemid 30311951)
26. Agabiti-Rosei E, Mancia G, O'Rourke MF, et al. Central blood pressure measurements and antihypertensive therapy: a consensus document. Hypertension 2007;50:154-160. (Pubitemid 46986036)
27. Safar ME, Blacher J, Pannier B, et al. Central pulse pressure and mortality in end-stage renal disease. Hypertension 2002;39:735-738. (Pubitemid 34252866)
28. Blacjher J, Safar ME, Guerin AP, et al. Aortic pulse wave velocity index and mortality in end-stage renal disease. Kidney Int 2003;63:1852-1860. (Pubitemid 36513333)
29. Mancia G, De Backer G, Dominiczak A, et al. Arterial Hypertension. 2007 Guidelines for the Management of Arterial Hypertension: The Task Force for the Management of Arterial Hypertension of the European Society of Hypertension (ESH) and of the European Society of Cardiology (ESC). J Hypertens 2007;25:1105-1187. (Pubitemid 46924065)
30. Mattace-Raso FU, van der Cammen TJ, Hofman A, et al. Arterial stiffness and risk of coronary heart disease and stroke: the Rotterdam Study. Circulation 2006;113:657-663.
31. Willum-Hansen T, Staessen JA, Torp-Pedersen C, et al. Prognostic value of aortic pulse wave velocity as index of arterial stiffness in the general population. Circulation 2006;113:664-670.
32. Mitchell GF, Hwang SJ, Vasan RS, et al. Arterial stiffness and cardiovascular events: the Framingham heart study. Circulation 2010;121:505-511. This study confirms that elevated PWV is associated with increased risk for a first cardiovascular event and improves risk prediction when added to standard risk factors.
33. Inoue N, Maeda R, Kawakami H, et al. Aortic pulse wave velocity predicts cardiovascular mortality in middle-aged and elderly Japanese men. Circ J 2009;73:549-553.
34. Cruickshank K, Riste L, Anderson SG, et al. Aortic pulse-wave velocity and its relationship to mortality in diabetes and glucose intolerance: an integrated index of vascular function? Circulation 2002;106:2085-2090. (Pubitemid 35192814)
35. Cecelja M, Chowienczyk P. Dissociation of aortic pulse wave velocity with risk factors for cardiovascular disease other than hypertension: a systematic review. Hypertension 2009;54:1328-1336.
36. Guerin AP, Blacher J, Pannier B, et al. Impact of aortic stiffness attenuation on survival of patients in end-stage renal failure. Circulation 2010;103:987-992. This study found that in patients with end-stage renal disease PWV is an independent predictor of mortality and that use of ACE inhibitors has a favorable effect on survival that is independent of its blood pressure lowering effects.
37. Townsend RR, Wimmer NJ, Chirinos JA, et al. Aortic PWV in chronic kidney disease: a CRIC ancillary study. Am J Hypertens 2009;23:282-289.
38. Pan CR, Schmaderer C, Roos M, et al. Comparing aortic stiffness in kidney transplant recipients, hemodialysis patients, and patients with chronic renal failure. Clin Transplant 2011;25:1-3.
39. Bachelet-Rousseau C, Kearney-Schwartz A, Frimat L, et al. Evolution of arterial stiffness after kidney transplantation. Nephrol Dial Transplant 2011 [Epub ahead of print].
40. Vlachopoulos C, Aznaouridis K, Stefanadis C. Prediction of cardiovascular events and all-cause mortality with arterial stiffness: a systematic review and meta-analysis. J Am Coll Cardiol 2010;55:1318-1327. This study found that an increase in aortic PWV by 1 m/s corresponded to an increased risk of 14% for cardiovascular events, 15% for cardiovascular-related mortality, and 15% for all-cause mortality.
41. Graham I, Atar D, Borch-Johnsen K, et al. European guidelines on cardiovascular disease prevention in clinical practice: executive summary: Fourth Joint Task Force of the European Society of Cardiology and other societies on cardiovascular disease prevention in clinical practice. Eur J Cardiovasc Prev Rehabil 2007;14(Suppl 2):E1-E40. (Pubitemid 47342420)
42. Weber T, Ammer M, Rammer M, et al. Noninvasive determination of carotidfemoral pulse wave velocity depends critically on assessment of travel distance: a comparison with invasive measurement. J Hypertens 2009;27:1624-1630.
43. The Reference Values for Arterial Stiffness Collaboration. Determinants of pulse wave velocity in healthy people and in the presence of cardiovascular risk factors: establishing normal and reference values. Eur Heart J 2010;31:2338-2350. This study established reference and normal values for PWV.
44. Chirinos JA, Kips JG, Roman MJ, et al. Ethnic differences in arterial wave reflections and normative equations for augmentation index. Hypertension 2011;57:1108-1116. This study found that there may be ethnic differences in arterial wave reflections.
45. Laurent S, Briet M, Boutouyrie P. Large and small artery cross-talk and recent morbidity-mortality trials in hypertension. Hypertension 2009;54:388-392.
46. Heagerty AM, Izzard AS. Small artery changes in hypertension. J Hypertens 1995;13:1560-1565.
47. Park JB, Schiffrin EL. Small artery remodeling is the most prevalent (earliest?) form of target organ damage in mild essential hypertension. J Hypertens 2001;19:921-930. (Pubitemid 32436957)
48. James MA, Watt PAC, Potter JF, et al. Pulse pressure and resistance artery structure in the elderly. Hypertension 1995;26:301-306.
49. O'Rourke MF, Safar ME. Relationship between aortic stiffening and microvascular disease in brain and kidney: cause and logic of therapy. Hypertension 2005;46:200-204. (Pubitemid 40946514)
50. Zieman SJ, Melenovsky V, Kass DA. Mechanisms, pathophysiology, and therapy of arterial stiffness. Arterioscler Thromb Vasc Biol 2005;25:932-943. (Pubitemid 40627836)
51. Dzau VJ. Significance of the vascular renin-angiotensin pathway. Hypertension 1986;8:553-559. (Pubitemid 16066758)
52. Marchesi C, Paradis P, Schiffrin EL. Role of the renin-angiotensin system in vascular inflammation. Trends Pharmacol Sci 2008;29:367-374.
53. Lacolley P, Labat C, Pujol A, et al. Increased carotid wall elastic modulus and fibronectin in aldosterone salt-treated rats: effects of eplerenone. Circulation 2002;106:2848-2853. (Pubitemid 35396986)
54. Blacher J, Amah G, Girerd X, et al. Association between increased plasma levels of aldosterone and decreased systemic arterial compliance in subjects with essential hypertension. Am J Hypertens 1997;10:1326-1334. (Pubitemid 28078735)
55. Palmer RM, Ashton DS, Moncada S. Vascular endothelial cells synthesize nitric oxide from L-arginine. Nature 1988;333:664-666.
56. Pollock JS, Forstermann U, Mitchell JA, et al. Purification and characterization of particulate endothelium-derived relaxing factor synthase from cultured and native bovine aortic endothelial cells. Proc Natl Acad Sci USA 1991;88:10480-10484. (Pubitemid 21915859)
57. Lamas S, Marsden PA, Li GK, et al. Endothelial nitric oxide synthase: molecular cloning and characterization of a distinct constitutive enzyme isoform. Proc Natl Acad Sci USA 1992;89:6348-6352.
58. Rees DD, Palmer RM, Moncada S. Role of endothelium-derived nitric oxide in the regulation of blood pressure. Proc Natl Acad Sci USA 1989;86:3375-3378. (Pubitemid 19129614)
59. Vallance P, Collier J, Moncada S. Effects of endothelium-derived nitric oxide on peripheral arteriolar tone in man. Lancet 1989;2:997-1000. (Pubitemid 19257913)
60. Raij L. Nitric oxide, salt sensitivity, and cardiorenal injury in hypertension. Semin Nephrol 1999;19:296-303. (Pubitemid 29200838)
61. Raij L. Hypertension and cardiovascular risk factors: role of the angiotensin II-nitric oxide interaction. Hypertension 2001;37:767-773. (Pubitemid 32199064)
62. Boffa JJ, Tharaux PL, Placier S, et al. Angiotensin II activates collagen type I gene in the renal vasculature of transgenic mice during inhibition of nitric oxide synthesis: evidence for an endothelin-mediated mechanism. Circulation 1999;100:1901-1908. (Pubitemid 29511144)
63. Jaimes EA, Galceran JM, Raij L. Angiotensin II induces superoxide anion production by mesangial cells. Kidney Int 1998;54:775-784. (Pubitemid 28397395)
64. Schulman HI, Zhou MS, Raij L. Interaction between nitric oxide and angiotensin II in the endothelium: role in atherosclerosis and hypertension. Hypertension 2006;24(Suppl 1):S45-S50. (Pubitemid 44336823)
65. Tolins JP, Shultz PJ, Raij L. Role of endothelium-derived relaxing factor in regulation of vascular tone and remodeling. Update on humoral regulation of vascular tone. Hypertension 1991;17:909-916.
66. Tropeano AI, Boutouyrie P, Pannier B, et al. Brachial pressure-independent reduction in carotid stiffness after long-term angiotensin-converting enzyme inhibition in diabetic hypertensives. Hypertension 2006;48:80-86. (Pubitemid 44313590)
67. Ting CT, Chen CH, Chang MS, Yin FC. Short-and long-term effects of antihypertensive drugs on arterial reflections, compliance, and impedance. Hypertension 1995;26:524-530.
68. Topouchian J, Brisac AM, Pannier B, et al. Assessment of the acute arterial effects of converting enzyme inhibition in essential hypertension: a doubleblind, comparative and crossover study. J Hum Hypertens 1998;12:181-187. (Pubitemid 28140288)
69. Topouchian J, Asmar R, Sayegh F, et al. Changes in arterial structure and function under trandolapril-verapamil combination in hypertension. Stroke 1999;30:1056-1064. (Pubitemid 29211627)
70. Asmar RG, London GM, O'Rourke ME, Safar ME. Improvement in blood pressure, arterial stiffness and wave reflections with a very low-dose perindopril/indapamide combination in hypertensive patient: a comparison with atenolol. Hypertension 2001;38:922-992.
71. Mahmud A, Feely J. Reduction in arterial stiffness with angiotensin II antagonist is comparable with and additive to ACE inhibition. Am J Hypertens 2002;15:321-325. (Pubitemid 34408971)
72. Lacourciere Y, Beliveau R, Conter HS, et al. Effects of perindopril on elastic and structural properties of large arteries in essential hypertension. Can J Cardiol 2004;20:795-799. (Pubitemid 39089608)
73. Mitchell GF, Arnold JM, Dunlap ME, et al. Pulsatile hemodynamic effects of candesartan in patients with chronic heart failure: the CHARM program. Eur J Heart Fail 2006;8:191-197. (Pubitemid 43240854)
74. Mitchell GF, Dunlap ME, Warnica W, et al. Long-term trandolapril treatment is associated with reduced aortic stiffness: the prevention of events with angiotensin-converting enzyme inhibition hemodynamic substudy. Hypertension 2007;49:1271-1277. (Pubitemid 46809368)
75. Lacolley P, Safar ME, Regnault V, Frohlich ED. Angiotensin II, mechanotransduction, and pulsatile arterial hemodynamics in hypertension. Am J Physiol Heart Circ Physiol 2009;297:H1567-H1575.
76. London GM, Asmar RG, O'Rourke MF, Safar ME. Mechanism (s) of selective systolic blood pressure reduction after a low-dose combination of perindopril/indapamide in hypertensive subjects: comparison with atenolol. J Am Coll Cardiol 2004;43:92-99. (Pubitemid 38045921)
77. Safar ME, Rizzoni D, Blacher J, et al. Macro and microvasculature in hypertension: therapeutic aspects. J Hum Hypertens 2008;22:590-595.
78. Williams B. Mechanical influences on vascular smooth muscle cell function. J Hypertens 1998;16:1929-1939.
79. Schiffrin EL. Remodeling of resistance arteries in essential hypertension and effects of antihypertensive treatment. Am J Hypertens 2004;17:1192-1200. (Pubitemid 40029420)
80. Agabiti-Rosei E, Heagerty AM, Rizzoni D. Effects of antihypertensive treatment on small artery remodelling. J Hypertens 2009;27:1107-1114.
81. Dahlof B, Devereux RB, Kjeldsen SE, et al. Cardiovascular morbidity and mortality in the Losartan Intervention for Endpoint Reduction in Hypertension Study (LIFE): a randomised trial against atenolol. Lancet 2002;359:995-1003. (Pubitemid 34286536)
82. Protogerou A, Blacher J, Stergiou GS, et al. Blood pressure response under chronic antihypertensive drug therapy: the role of aortic stiffness in the REASON (Preterax in Regression of Arterial Stiffness in a Controlled Double-Blind) study. J Am Coll Cardiol 2009;53:445-451.
83. Williams B, Lacy PS, Thom SM, et al. Differential impact of blood pressurelowering drugs on central aortic pressure and clinical outcomes: principal results of the Conduit Artery Function Evaluation (CAFE) study. Circulation 2006;113:1213-1225.
84. Ting CT, Brin KP, Lin SJ, et al. Arterial hemodynamics in human hypertension. J Clin Invest 1986;78:1462-1471. (Pubitemid 17219508)
85. Medical Research Council Working Party. Medical Research Council trial of treatment of hypertension in older adults: principal results. Br Med J 1992;304:405-412.
86. Turnbull F, and the Blood Pressure Lowering Treatment Trialists' Collaboration. Effects of different blood-pressure-lowering regimens on major cardiovascular events: results of prospectively-designed overviews of randomised trials. Lancet 2003;362:1527-1535. (Pubitemid 37410190)
87. Khan NA, Hemmelgarn BR, Herman RJ. The 2009 Canadian Hypertension Education Program (CHEP) recommendations for the management of hypertension. Part 2: Therapy. Can J Cardiol 2009;25:287-298.
88. The National Collaborating Center for Chronic Conditions (UK). Guidelines for management of hypertension in adults in primary care. London: Royal college of Physicians. 2006. pp. 18-22.
89. Dahlof B, Sever PS, Poulter NR, et al. Prevention of cardiovascular events with an antihypertensive regimen of amlodipine adding perindopril as required versus atenolol adding bendroflumethiazide as required, in the Anglo-Scandinavian Cardiac Outcomes Trial-Blood Pressure Lowering Arm. (ASCOT-BPLA): a multicentre randomised controlled trial. Lancet 2005;366:895-906. (Pubitemid 41265663)
90. Matsui Y, Eguchi K, O'Rourke MF, et al. Differential effects between a calcium channel blocker and a diuretic when used in combination with angiotensin II receptor blocker on central aortic pressure in hypertensive patients. Hypertension 2009;54:716-723.
91. Kampus P, Serg M, Kals J, et al. Differential effects of nebivolol and metoprolol on central aortic pressure and left ventricular wall thickness. Hypertension 2011;57:1122-1128. This study evaluated the effects of nebivolol on measures of central hemodynamics.
92. Zhou MS, Schulman IH, Jaimes EA, Raij L. Thiazide diuretics, endothelial function, and vascular oxidative stress. J Hypertens 2008;26:494-500. (Pubitemid 351317258)
93. Jamerson K, Weber MA, Bakris GL, et al. Benazepril plus amlodipine or hydrochlorothiazide for hypertension in high-risk patients. N Engl J Med 2008;23:2417-2428.
94. Law MR, Morris JK, Wald NJ. Use of blood pressure lowering drugs in the prevention of cardiovascular disease: meta-analysis of 147 randomised trials in the context of expectations from prospective epidemiological studies. BMJ 2009;338:b1665 doi:10.11 36/bmj.b1665.
95. Shige H, Dart A, Nestel P. Simvastatin improves arterial compliance in the lower limb but not in the aorta. Atherosclerosis 2001;155:245-250. (Pubitemid 32167146)
96. Ichihara A, Hayashi M, Ryuzaki M, et al. Fluvastatin prevents development of arterial stiffness in haemodialysis patients with type 2 diabetes mellitus. Nephrol Dial Transplant 2002;17:1513-1517.
97. Kontopoulos AG, Athyros VG, Pehlivanidis AN, et al. Long-term treatment effect of atorvastatin on aortic stiffness in hypercholesterolaemic patients. Curr Med Res Opin 2003;19:22-27. (Pubitemid 36378316)
98. Pirro M, Schillaci G, Mannarino MR, et al. Effects of rosuvastatin on 3-nitrotyrosine and aortic stiffness in hypercholesterolemia. Nutr Metab Cardiovasc Dis 2007;17:436-441. (Pubitemid 47079109)
99. Williams B, Lacy PS, Cruickshank JK, et al. Impact of statin therapy on central aortic pressures and hemodynamics: principal results of the Conduit Artery Function Evaluation-Lipid-Lowering Arm (CAFE-LLA) study. Circulation 2009;119:53-61.